Header Logo

Connection

FERDINANDOS SKOULIDIS to Drug Approval

Back to Details
This is a "connection" page, showing publications FERDINANDOS SKOULIDIS has written about Drug Approval.
FERDINANDOS SKOULIDIS
Connection Strength
0.126
Drug Approval
  1. Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor. Clin Cancer Res. 2016 Nov 01; 22(21):5177-5182.
    View in: PubMed
    Score: 0.126
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.